Dual Inhibitors of Main Protease (M^Pro) and Cathepsin L as Potent Antivirals against SARS-CoV2

Abstract

Given the current impact of SARS-CoV2 and COVID-19 on human health and the global economy, the development of direct acting antivirals is of paramount importance. Main protease (M^Pro), a cysteine protease that cleaves the viral polyprotein, is essential for viral replication. Therefore, M^Pro is a novel therapeutic target. We identified two novel M^Pro inhibitors, D-FFRCMKyne and D-FFCitCMKyne, that covalently modify the active site cysteine (C145) and determined cocrystal structures. Medicinal chemistry efforts led to <b>SM141</b> and <b>SM142</b>, which adopt a unique binding mode within the M^Pro active site. Notably, these inhibitors do not inhibit the other cysteine protease, papain-like protease (PL^Pro), involved in the life cycle of SARS-CoV2. <b>SM141</b> and <b>SM142</b> block SARS-CoV2 replication in hACE2 expressing A549 cells with IC₅₀ values of 8.2 and 14.7 nM. Detailed studies indicate that these compounds also inhibit cathepsin L (CatL), which cleaves the viral S protein to promote viral entry into host cells. Detailed biochemical, proteomic, and knockdown studies indicate that the antiviral activity of <b>SM141</b> and <b>SM142</b> results from the dual inhibition of M^Pro and CatL. Notably, intranasal and intraperitoneal administration of <b>SM141</b> and <b>SM142</b> lead to reduced viral replication, viral loads in the lung, and enhanced survival in SARS-CoV2 infected K18-ACE2 transgenic mice. In total, these data indicate that <b>SM141</b> and <b>SM142</b> represent promising scaffolds on which to develop antiviral drugs against SARS-CoV2.